Guaifenesin

Description

No description information is available for the drug.

Uses and Indications

This drug is indicated for the temporary symptomatic relief of congested chests and cough.

There are no teratogenic or nonteratogenic effects associated with this medication.

Dosage and Administration

Adults and children 12 years of age and over are advised to take one caplet daily. For children under 12 years of age, the use of this medication is not recommended. It is important to note that the total dosage should not exceed four caplets within a 24-hour period.

Healthcare professionals should ensure that patients are aware of these dosing guidelines to prevent potential overdose and to promote safe usage of the medication.

Contraindications

Use is contraindicated in patients who consume alcohol, benzodiazepines, or opioids due to the potential for adverse interactions. Additionally, exceeding the recommended dosage is contraindicated to prevent the risk of overdose and associated complications. No other specific contraindications have been identified in the provided data.

Warnings and Precautions

A persistent cough may indicate an underlying serious condition. Healthcare professionals should advise patients to seek medical consultation if a cough persists for more than one week, recurs frequently, or is accompanied by additional symptoms such as fever, rash, or a persistent headache.

In the event that a cough lasts longer than seven days, it is imperative for patients to discontinue use and consult their physician or healthcare provider for further evaluation and management.

In cases of suspected overdose, immediate medical assistance is crucial. Patients should be instructed to contact a medical professional or reach out to a Poison Control Center at 1-800-222-1222 without delay.

Side Effects

Patients may experience a range of adverse reactions associated with the use of this medication. A persistent cough may indicate a serious underlying condition; therefore, if a cough persists for more than one week, recurs, or is accompanied by fever, rash, or persistent headache, patients are advised to consult a healthcare professional.

In the context of over-the-counter (OTC) use, patients should discontinue use and seek medical advice if their cough lasts longer than seven days. Additionally, it is recommended that patients consult a doctor prior to use if they have a persistent or chronic cough, such as that which occurs with smoking, asthma, chronic bronchitis, or emphysema. Patients should also seek medical advice if their cough is accompanied by excessive phlegm (mucus).

These precautions are essential to ensure the safe use of the medication and to address any potential serious conditions that may be indicated by the symptoms described.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Guaifenesin. Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under 12 years of age should not use this medication. For adolescents aged 12 years and older, the recommended dosage is one caplet per day.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. It is advisable to monitor these patients closely for any adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The potential risks and benefits must be carefully weighed, as the effects on fetal outcomes and lactation are not fully established. It is essential for women of childbearing potential to seek medical advice to ensure the safety of both the mother and the developing fetus.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data regarding the excretion of this medication in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

There is no specific information available regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution when prescribing to patients with reduced kidney function, as the absence of detailed guidance necessitates careful clinical judgment. Regular monitoring of renal function may be advisable in this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant and prepared for potential scenarios involving overdose.

Healthcare providers should be aware that the clinical presentation of an overdose may vary depending on the substance involved and the individual patient’s characteristics. Symptoms of overdose can range from mild to severe and may include altered mental status, cardiovascular instability, respiratory distress, and gastrointestinal disturbances.

In the event of suspected overdosage, immediate medical evaluation is recommended. Healthcare professionals should assess the patient's vital signs and conduct a thorough clinical examination. Supportive care should be initiated as necessary, including airway management, oxygen supplementation, and intravenous fluids.

If the specific agent involved in the overdose is known, appropriate antidotes or treatments should be administered as per established guidelines. Continuous monitoring of the patient’s condition is crucial, and further interventions may be required based on the evolving clinical picture.

It is advisable for healthcare professionals to consult local poison control centers or toxicology experts for guidance on managing specific overdose cases, as they can provide valuable insights and recommendations tailored to the situation at hand.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's safety profile in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are provided in the insert.

Patient Counseling

Healthcare providers should advise patients to keep this medication out of reach of children to prevent accidental ingestion. In the event of an overdose, patients should be instructed to seek medical help immediately or contact a Poison Control Center at 1-800-222-1222.

Patients should be informed to discontinue use and consult a physician if their cough persists for more than 7 days. It is essential to emphasize that patients must not exceed the recommended dosage while using this product. Additionally, they should be cautioned against consuming alcohol, benzodiazepines, or opioids during treatment.

Healthcare providers should encourage patients to seek medical advice before using this product if they have a persistent or chronic cough, particularly if it is associated with smoking, asthma, chronic bronchitis, or emphysema. Patients should also be advised to consult a doctor if their cough is accompanied by excessive phlegm (mucus).

Storage and Handling

The product is supplied in a configuration that includes specific NDC numbers, which should be referenced for accurate identification. It is essential to store the product at a controlled room temperature of 25°C (77°F), with permissible excursions between 15°C and 30°C (59°F to 86°F).

The product must be kept in a dry environment, and it is crucial to avoid exposure to heat to maintain its integrity and efficacy. Proper handling and storage conditions are vital to ensure the product remains within the specified temperature range and is protected from moisture and heat.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Guaifenesin, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)